Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Report Date: August 11, 2025
Reporting Period: The filing announces financial results for the three and six months ended June 30, 2025.
Key Financial Metrics
The provided text is a cover sheet for a Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, no numerical values for these metrics are available in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of a press release containing the results for the period ended June 30, 2025.
Guidance, Outlook, and Management Commentary
Management Action: The Company issued a press release on August 11, 2025, and scheduled a conference call for 8:00 AM ET on the same date to discuss the results.
Legal Disclaimer: The information in Item 2.02 and the attached press release is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings unless expressly stated.
Guidance/Risks: No specific guidance, outlook, risks, or contingencies are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net income, and cash flow figures for the three and six months ended June 30, 2025.
- Listen to the conference call held on August 11, 2025, for management commentary on operational performance and future outlook.
- Verify the status of Mark Frost as Interim Chief Financial Officer and any implications for financial reporting continuity.
- Confirm whether the press release contains updated forward-looking guidance or material risk factors not present in prior filings.